Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High – Still a Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $39.39 and last traded at $39.25, with a volume of 37092 shares trading hands. The stock had previously closed at $38.55.

Analysts Set New Price Targets

A number of research firms have recently commented on SUPN. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an “overweight” rating and a $57.00 price target on the stock.

Supernus Pharmaceuticals Stock Up 2.6 %

The company has a market cap of $2.18 billion, a price-to-earnings ratio of 36.97 and a beta of 0.90. The business has a fifty day simple moving average of $36.83 and a 200 day simple moving average of $34.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same period last year, the company posted ($0.29) EPS. The company’s revenue was up 14.2% on a year-over-year basis. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares of the company’s stock, valued at $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its holdings in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at $791,000. Geode Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the period. Franklin Resources Inc. grew its stake in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after purchasing an additional 109,088 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.